Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 226

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 226
---
 each January 1 by 10% of the aggregate number of fully diluted shares of our common stock from the first day of the preceding calendar year to the first day of the current calendar year or such lesser number as determined by our board of directors. On January 1, 2025, the number of shares of common stock available under the 2021 Plan increased to 156,512as per the Evergreen Feature in the 2021 Plan. Under the 2021 Plan, stock options and stock appreciation rights are granted at exercise prices determined by the Board of Directors which cannot be less than 100% of the estimated fair market value of the common stock on the grant date. Incentive stock options granted to any stockholders holding 10% or more of the Company’s equity cannot be granted with an exercise price of less than 110% of the estimated fair market value of the common stock on the grant date and such options are not exercisable after five yearsfrom the grant date. As of March 31, 2025, there were 97,880shares available for future grants under the 2021 Plan. Restricted Stock Units As of March 31, 2025 and December 31, 2024, the Company has a total of 3Rollover RSU awards for shares of common stock outstanding, respectively. As of March 31, 2025, 3Rollover RSU awards have fully vested but are unissued and no Rollover RSU awards have been forfeited. Each Rollover RSU award converts to one share of common stock. Restricted Stock Awards On February 11, 2025, 58,568RSAs were granted to employees and the Board of Directors which resulted in a fair value of $ 0.2million of stock-based compensation expense based on the Company’s stock price on the date of grant. The awards were granted from shares available under the 2021 Plan with 57,665vesting 100% on the date of grant and 903vesting 50% on the date of grant, with 50% vesting oneyear thereafter. Stock Options The Company has granted stock options, all of which have fully vested in prior periods.Stock options have a maximum term of 3or 10years. There were nostock options granted during the three months ended March 31, 2025 and 2024. As of March 31, 2025, the Company had 64stock options outstanding and